UT-105
UT-105 is an orally active, selective androgen receptor (AR) degrader. UT-105 binds to the N-terminal domain of AR, inhibits the transactivation of AR, blocks the recruitment of AR to androgen response elements, and induces AR degradation. UT-105 inhibits the JAK-STAT signaling pathway, including reducing the expression of interferon-stimulated genes, inhibiting the phosphorylation of STAT1 and STAT3, and blocking the recruitment of STAT1 to response elements. UT-105 exhibits anticancer activity against AR-positive triple-negative breast cancer (TNBC). UT-105 can be used in the research of selective androgen receptor modulator-resistant ER-positive breast cancer and triple-negative breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 2388536-21-6
- Formula: C15H11F3N6O2
- Molecular Weight:364.28
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[2]|
STAT1 |
STAT3 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| COS-7 | IC50 |
59.4 nM
|
Inhibition of wild-type AR transactivation in COS7 cells in the presence of 0.1 nM synthetic androgen agonist R1881, measured via luciferase assay after 24 h treatment.
Inhibition of wild-type AR transactivation in COS7 cells in the presence of 0.1 nM synthetic androgen agonist R1881, measured via luciferase assay after 24 h treatment.
|
37979170 |
| COS-7 | IC50 |
36.5 nM
|
Inhibition of enzalutamide-resistant AR F876L transactivation in COS7 cells in the presence of 0.1 nM synthetic androgen agonist R1881, measured via luciferase assay after 24 h treatment.
Inhibition of enzalutamide-resistant AR F876L transactivation in COS7 cells in the presence of 0.1 nM synthetic androgen agonist R1881, measured via luciferase assay after 24 h treatment.
|
37979170 |
In Vitro
UT-105 (24 h) potently inhibits wild-type and Enzalutamide (HY-70002)-resistant mutant AR transactivation in COS7 cells, with IC50 values of 59.4 nM and 36.5 nM, respectively, and shows no cross-reactivity with GR or MR[2].
UT-105 (1-10 μM; 24 h) degrades AR protein in LNCaP prostate cancer cells when treated in the presence of 0.1 nM R1881[2].
UT-105 (10 μM; overnight at 4°C for binding assay; 100 μM; 4 h at room temperature for stabilization assay) binds to the AR NTD, inducing a conformational change, and stabilizes purified AR AF-1 and AR-V7 proteins in cell-free biochemical assays[2].
UT-105 (3 μM; 20 h) reverses androgen-responsive gene expression and significantly downregulates the androgen response pathway in MDA-MB-453 LAR TNBC cells when treated in the presence of 0.1 nM R1881[2].
UT-105 (10 μM; 2 weeks) inhibits colony formation in AR-V7-expressing MDA-MB-453-V7, MDA-MB-231-V7, and MFM223-V7 TNBC cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LNCaP prostate cancer cells
-
Concentration:1-10 μM (in presence of 0.1 nM R1881)
-
Incubation Time:24 h
-
Result:Downregulated AR protein expression in a concentration-dependent manner relative to vehicle control.
In Vivo
UT-105 (60 mg/kg; p.o.; once daily; for 28 consecutive days) potently inhibits the growth of MDA-MB-453 LAR TNBC xenografts, with a tumor growth inhibition rate of >90%[2].
UT-105 (60 mg/kg; p.o.; once daily; for 28 consecutive days) potently inhibits the growth of the UT-1355 LAR-AR-SV triple-negative breast cancer PDX model, with a tumor growth inhibition rate >90% and reduced tumor weight[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG (female)[2]
-
Dosage:60 mg/kg
-
Administration:p.o.; daily; 28 days
-
Result:Achieved >90% tumor growth inhibition (TGI).
Showed no effect on body weight of tumor-bearing mice.\nAchieved >90% tumor growth inhibition (TGI).
Showed no effect on body weight of tumor-bearing mice.
Significantly reduced tumor weights compared with vehicle and enzalutamide groups.
Chemical Information
-
CAS No. 2388536-21-6
-
Molecular Weight 364.28
-
Formula C15H11F3N6O2
-
SMILES
N#CC(C=N1)=CN1C[C@](C)(O)C(NC2=CN=C(C#N)C(C(F)(F)F)=C2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- UT-105
- 2388536-21-6
- UT105
- UT 105
- Androgen Receptor
- JAK
- STAT
- triple-negative breast cancer
- androgen receptor
- human wild-type AR
- human AR F876L mutant
- selective androgen receptor modulator-resistant breast cancer
- JAK-STAT signaling pathway
- AR-V7
- LNCaP prostate cancer cells
- COS7 cells
- MDA-MB-453 LAR TNBC cells
- Inhibitor
- inhibitor
- inhibit